Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the HER2Climb-05 trial and how it impacts treatment for HER2+ metastatic breast cancer.
Advertisement
Recommendations
Advertisement
Conexiant's News Site Is Now MDSpire News.
You now have access to the trusted editorial news and specialty content you've known from the Conexiant news site—all within the MDSpire experience.
Learn more
